Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Contact us
Product pipeline
ELND005
Gastrin-based therapies
Anti-inflammation
Anti-glycemic compounds
Current partnership
In/Out-licensing opportunity
ELND005 Phase II
TT-223 Phase II
TT-223 + GLP-1 Phase Ib
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2010
Press release archive
Webcast and presentation
INVESTOR relations
Stock Quotes
Financial Reports
Analyst Coverage
Request Information
E-mail Alert
To request additional information, please fill out the form below:
Personal Information
First Name:
Last Name:
E-mail Address:
Organization:
Address Line 1:
Address Line 2:
City:
Province/State:
Postal/Zip code:
Country:
Request:
© 2010 Transition Therapeutics Inc.